|
⚲
|
| Slate Pharmaceuticals Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001469231 |
| Sale | 2009-08-07 ($2.8 M Offered, $2.8 M Sold) |
| Fund | |
| Phone | 9196828800 |
| Address | 318 Blackwell Street Durham, 27701 |
| Source | [EDGAR] |
| Fund AUM and Sold ($M) |
|---|
| Fund Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Directors | 2011 - 2025 |
|---|---|
| Kenneth Couch | |
| Richard Deschutter | |
| Douglas Eckert | |
| Anthony Wild | |
| Robert Whitehead | |
| Michael Ford | |
| Trygve Mikkelsen | |
| William Dahl |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Hattem Dave S.
✚
|
0.0 | |
|
Hatteras Venture Partners IV SBIC, LP
✚
|
0.0 | |
|
Vicon Holding & Investment Company, LLC
✚
|
0.0 | |
|
Victory Innovations Holdings, LLC
✚
|
0.0 | |
|
Victory Investment Group LLC
✚
|
0.0 | |
|
AHEAD Parent Holdings, LP
✚
|
0.0 | |
|
Canaan Partners VII LLC
✚
|
0.0 | |
|
Victress Capital Opportunity Fund, LLC - Series One
✚
|
0.0 | |
|
Fund 00397 a series of Assure Labs GB 2022, LLC
✚
|
0.0 | |
|
Hathhorn Marc E.
✚
|
0.0 |